1 / 12

The AIDS Vaccine Policy Agenda

The AIDS Vaccine Policy Agenda. Holly J. Wong Vice President, Public Policy International AIDS Vaccine Initiative (IAVI). Vienna, Austria International AIDS Society Conference July 18, 2010. A Time of Unprecedented Scientific Progress…. And Fiscal Constraint.

stew
Download Presentation

The AIDS Vaccine Policy Agenda

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The AIDS Vaccine Policy Agenda Holly J. Wong Vice President, Public Policy International AIDS Vaccine Initiative (IAVI) Vienna, Austria International AIDS Society Conference July 18, 2010

  2. A Time of Unprecedented Scientific Progress… And Fiscal Constraint

  3. Policy Priorities in this Climate To sustain an enabling environment for continued AIDS vaccine innovation Identifying and addressing obstacles to scientific innovation Demonstrating the value of an AIDS vaccine; advocating for strengthened political and financial support Developing new financing and incentive mechanisms for global health R&D Harnessing AIDS vaccine investments for economic development

  4. Identifying and Addressing Obstacles to Scientific Innovation Enhancing Brazil’s Capacity for Biopharmaceutical Innovation Brazilian STD, AIDS and Hepatitis Department Chinese Ministry of Health

  5. Identifying and Addressing Obstacles to Scientific Innovation The state of the AIDS vaccine field Prize competitions could… • Accelerate the time it takes to solve the problem; • Allow for multiple approaches to achieve the same goal Urgent need to accelerate AIDS vaccine R&D Urgent need to accelerate AIDS vaccine R&D • Generate excitement and publicity and elevate the profile of the field; Need for innovative approaches and new thinking • Cast a wide net to attract participants from outside the field of interest; ? • Establish a community of solvers ? ?

  6. Demonstrating the Value of an AIDS Vaccine Potential Impact of an AIDS Vaccine in Developing Countries • Key findings: • Even with full scale-up of existing prevention and treatment, new HIV infections will persist in developing countries • An AIDS vaccine with 50% efficacy given to 30% of the adult population would avert 24% of new infections 2015-2030, or 5.6 million • Preliminary findings suggest that an AIDS vaccine would be cost saving. Kenya AIDS Vaccine Initiative Evandro Chagas Clinical Research Inst. Makerere Univ. School of Public Health

  7. Developing New Financing Mechanisms to Advance Global Health R&D • Insufficient • Unpredictable • Inflexible • Short-term Traditional funding for AIDS vaccine R&D is: New financing mechanisms could be designed to bring additional resources and accelerate global health R&D by: • Accessing funding from untapped resources • Mitigating political and economic shocks • Making future economic value of products available now • Supporting scientific risk-taking • Creating flexibility to facilitate rapid change of direction as new science emerges • Policy priorities: • Develop a financing mechanism for global health R&D, or AIDS vaccine R&D • Expand existing mechanisms to include R&D

  8. Harnessing AIDS Vaccine Investments for Economic Development • Investments in AIDS vaccine R&D can contribute to broader economic development goals: • In the longer term: by reducing disease burdens, increasing workforce productivity • In the near term: collaborative research with developing country partners can strengthen capacities for science and technology, contributing to growth and diversification of jobs, firms, and economies • Policy priority in this area: • Identify and advocate for best practices in maximizing development impact of global health R&D investments

  9. Advocating for Strengthened Political and Financial Support • Policy Advocacy Priorities: • Tracking available resources for AIDS vaccine R&D to make the case for increased and diversified investment • Demonstrating the spillover benefits of AIDS vaccine investment on development and health systems strengthening • Positioning AIDS vaccines as a tool to help achieve universal access and the MDGs

  10. Annual Investments in HIV Vaccine R&D 2000-2009 US$ Millions

  11. Conclusions • At a time of scientific progress and fiscal constraint, it is critical to sustain and increase political and financial support to continue advancing AIDS vaccine science. • Policy reforms are key to creating an enabling environment to accelerate AIDS vaccine R&D. • Identifying new funders and developing new R&D financing mechanisms are urgent priorities • Policies to spur scientific innovation and engage the private sector are also key priorities to accelerate aids vaccine science

More Related